ArticleCurrent topics in microbiology and immunology2022
Chronic Chikungunya Virus Disease.
Article in Current topics in microbiology and immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Identification and characterization of novel chikungunya virus polymerase inhibitors.Journal of virology · 2026Article
- Unveiling Clinical Phenotypes in Chronic Chikungunya Disease: Insights from a Brazilian Observational Study.Tropical medicine and infectious disease · 2026Article
- Chikungunya virus persists in joint-associated macrophages and promotes chronic disease in mice.Nature microbiology · 2026Article
- Pathogenesis of Chronic Arthritis Due to Chikungunya Virus and Advances in Vaccine Development.Viruses · 2026Review
- GM-CSF and M-CSF Driven Differentiation Differentially Regulates Chikungunya Virus Infection and Antiviral Responses in Human Monocyte-Derived Macrophages.bioRxiv : the preprint server for biology · 2026Article
- Article
- Continuous detection of Chikungunya Virus in a passive surveillance system in southern Thailand, 2012-2019.PLoS neglected tropical diseases · 2025Article
- Mutations in chikungunya virus nsP4 decrease viral fitness and sensitivity to the broad-spectrum antiviral 4'-Fluorouridine.PLoS pathogens · 2025Article
- Article
- Chikungunya virus infection disrupts MHC-I antigen presentation via nonstructural protein 2.PLoS pathogens · 2024Article
- Chikungunya virus infection disrupts lymph node lymphatic endothelial cell composition and function via MARCO.JCI insight · 2024Article
- Unlocking the antiviral potential of rosmarinic acid against chikungunya virus via IL-17 signaling pathway.Frontiers in cellular and infection microbiology · 2024Article
- Spatial-temporal distribution of chikungunya virus in Brazil: a review on the circulating viral genotypes andFrontiers in public health · 2024Review
- Chikungunya virus infection disrupts MHC-I antigen presentation via nonstructural protein 2.bioRxiv : the preprint server for biology · 2023Article
- Chikungunya virus cell-to-cell transmission is mediated by intercellular extensions in vitro and in vivo.Nature microbiology · 2023Article
- Virological, Serological and Clinical Analysis of Chikungunya Virus Infection in Thai Patients.Viruses · 2022Article
- Two Conserved Phenylalanine Residues in the E1 Fusion Loop of Alphaviruses Are Essential for Viral Infectivity.Journal of virology · 2022Article
- Increased platelet activation and platelet-inflammasome engagement during chikungunya infection.Frontiers in immunology · 2022Article
- Role of cytokines, chemokines, C3a, and mannose-binding lectin in the evolution of the chikungunya infection.American journal of clinical and experimental immunology · 2022Article
- Cognitive Dysfunction of Chikungunya Virus Infection in Older Adults.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that has caused both small- and large-scale epidemics of incapacitating musculoskeletal disease across the globe. A substantial proportion of infected individuals experience debilitating arthralgia and/or arthritis that can persist in relapsing or continuous forms for months to years, an occurrence that appears independent of viral strain and outbreak location. Due to the lack of CHIKV-specific vaccine or therapeutics, treatment of chronic CHIKV disease is limited to supportive care. Although the epidemiologic and molecular mechanisms that dictate resolution or chronicity of CHIKV disease remain unclear, several risk factors and immunological responses have been implicated in the development of chronic CHIKV disease. Mounting evidence from animal models and limited case studies indicates that chronic disease is likely a result of induced autoimmunity and/or viral persistence in joint-associated tissue. Due to the global spread and explosive, often unpredictable nature of CHIKV epidemics, concerted efforts to obtain a more precise understanding of the development and maintenance of chronic CHIKV disease must be at the forefront of investigative endeavors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.